FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3098343886> ?p ?o ?g. }

• W3098343886 abstract "Background High-risk locally advanced cervical cancer (CC) has a poor prognosis, and >50% of patients recur in 2 years. Concurrent chemoradiotherapy (CRT) may enhance the immunostimulatory activity of the PD-1 inhibitor pembrolizumab. After KEYNOTE-158, in which pembrolizumab demonstrated durable antitumor activity, pembrolizumab monotherapy was approved for patients with PD-L1–positive recurrent or metastatic CC who progressed during or after chemotherapy. ENGOT-cx11/KEYNOTE-A18 (NCT04221945) is a phase 3, randomized, placebo-controlled study evaluating pembrolizumab with concurrent CRT in locally advanced CC. Trial design Approximately 980 patients with high-risk, locally advanced, histologically confirmed CC who have not received systemic therapy, immunotherapy, definitive surgery, or radiation will be randomized 1:1 to receive 5 cycles of pembrolizumab 200 mg Q3W + CRT (5 cycles [with optional 6th cycle] of cisplatin 40 mg/m2 Q1W + external beam radiotherapy [EBRT] followed by brachytherapy) followed by 15 cycles of pembrolizumab 400 mg Q6W or 5 cycles of placebo Q3W + CRT followed by 15 cycles of placebo Q6W. Randomization is stratified by planned EBRT type, cancer stage at screening, and planned total radiotherapy dose. Treatment will continue until patient receives ≤20 cycles of pembrolizumab (5 cycles 200 mg Q3W, 15 cycles 400 mg Q6W) vs placebo (~2 years) or until disease progression, unacceptable toxicity, or withdrawal. Primary endpoints are PFS per RECIST v1.1 by blinded independent central review and OS. Secondary endpoints include PFS at 2 years, OS at 3 years, complete response at 12 weeks, ORR, PFS and OS in PD-L1–positive patients, and safety. Enrollment is ongoing." @default.
• W3098343886 created "2020-11-23" @default.
• W3098343886 creator A5002555374 @default.
• W3098343886 creator A5009234043 @default.
• W3098343886 creator A5012951330 @default.
• W3098343886 creator A5046110437 @default.
• W3098343886 creator A5053574015 @default.
• W3098343886 creator A5054372225 @default.
• W3098343886 creator A5061939825 @default.
• W3098343886 creator A5066133616 @default.
• W3098343886 creator A5066888430 @default.
• W3098343886 creator A5066979556 @default.
• W3098343886 creator A5067053417 @default.
• W3098343886 creator A5070839902 @default.
• W3098343886 creator A5071527937 @default.
• W3098343886 creator A5073232598 @default.
• W3098343886 creator A5073534969 @default.
• W3098343886 creator A5073787373 @default.
• W3098343886 creator A5079485962 @default.
• W3098343886 creator A5083659627 @default.
• W3098343886 creator A5085728973 @default.
• W3098343886 creator A5090765165 @default.
• W3098343886 date "2020-11-01" @default.
• W3098343886 modified "2023-10-18" @default.
• W3098343886 title "164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer" @default.
• W3098343886 doi "https://doi.org/10.1136/ijgc-2020-igcs.142" @default.
• W3098343886 hasPublicationYear "2020" @default.
• W3098343886 type Work @default.
• W3098343886 sameAs 3098343886 @default.
• W3098343886 citedByCount "0" @default.
• W3098343886 crossrefType "proceedings-article" @default.
• W3098343886 hasAuthorship W3098343886A5002555374 @default.
• W3098343886 hasAuthorship W3098343886A5009234043 @default.
• W3098343886 hasAuthorship W3098343886A5012951330 @default.
• W3098343886 hasAuthorship W3098343886A5046110437 @default.
• W3098343886 hasAuthorship W3098343886A5053574015 @default.
• W3098343886 hasAuthorship W3098343886A5054372225 @default.
• W3098343886 hasAuthorship W3098343886A5061939825 @default.
• W3098343886 hasAuthorship W3098343886A5066133616 @default.
• W3098343886 hasAuthorship W3098343886A5066888430 @default.
• W3098343886 hasAuthorship W3098343886A5066979556 @default.
• W3098343886 hasAuthorship W3098343886A5067053417 @default.
• W3098343886 hasAuthorship W3098343886A5070839902 @default.
• W3098343886 hasAuthorship W3098343886A5071527937 @default.
• W3098343886 hasAuthorship W3098343886A5073232598 @default.
• W3098343886 hasAuthorship W3098343886A5073534969 @default.
• W3098343886 hasAuthorship W3098343886A5073787373 @default.
• W3098343886 hasAuthorship W3098343886A5079485962 @default.
• W3098343886 hasAuthorship W3098343886A5083659627 @default.
• W3098343886 hasAuthorship W3098343886A5085728973 @default.
• W3098343886 hasAuthorship W3098343886A5090765165 @default.
• W3098343886 hasBestOaLocation W30983438861 @default.
• W3098343886 hasConcept C121608353 @default.
• W3098343886 hasConcept C126322002 @default.
• W3098343886 hasConcept C141071460 @default.
• W3098343886 hasConcept C142724271 @default.
• W3098343886 hasConcept C143998085 @default.
• W3098343886 hasConcept C168563851 @default.
• W3098343886 hasConcept C203092338 @default.
• W3098343886 hasConcept C204243189 @default.
• W3098343886 hasConcept C204787440 @default.
• W3098343886 hasConcept C27081682 @default.
• W3098343886 hasConcept C2777701055 @default.
• W3098343886 hasConcept C2778220009 @default.
• W3098343886 hasConcept C2778424827 @default.
• W3098343886 hasConcept C2780057760 @default.
• W3098343886 hasConcept C509974204 @default.
• W3098343886 hasConcept C71924100 @default.
• W3098343886 hasConceptScore W3098343886C121608353 @default.
• W3098343886 hasConceptScore W3098343886C126322002 @default.
• W3098343886 hasConceptScore W3098343886C141071460 @default.
• W3098343886 hasConceptScore W3098343886C142724271 @default.
• W3098343886 hasConceptScore W3098343886C143998085 @default.
• W3098343886 hasConceptScore W3098343886C168563851 @default.
• W3098343886 hasConceptScore W3098343886C203092338 @default.
• W3098343886 hasConceptScore W3098343886C204243189 @default.
• W3098343886 hasConceptScore W3098343886C204787440 @default.
• W3098343886 hasConceptScore W3098343886C27081682 @default.
• W3098343886 hasConceptScore W3098343886C2777701055 @default.
• W3098343886 hasConceptScore W3098343886C2778220009 @default.
• W3098343886 hasConceptScore W3098343886C2778424827 @default.
• W3098343886 hasConceptScore W3098343886C2780057760 @default.
• W3098343886 hasConceptScore W3098343886C509974204 @default.
• W3098343886 hasConceptScore W3098343886C71924100 @default.
• W3098343886 hasLocation W30983438861 @default.
• W3098343886 hasOpenAccess W3098343886 @default.
• W3098343886 hasPrimaryLocation W30983438861 @default.
• W3098343886 hasRelatedWork W1051628 @default.
• W3098343886 hasRelatedWork W12229326 @default.
• W3098343886 hasRelatedWork W12563037 @default.
• W3098343886 hasRelatedWork W13888011 @default.
• W3098343886 hasRelatedWork W14239869 @default.
• W3098343886 hasRelatedWork W1852338 @default.
• W3098343886 hasRelatedWork W18786604 @default.
• W3098343886 hasRelatedWork W3582852 @default.
• W3098343886 hasRelatedWork W5806089 @default.
• W3098343886 hasRelatedWork W8718024 @default.
• W3098343886 isParatext "false" @default.
• W3098343886 isRetracted "false" @default.
• W3098343886 magId "3098343886" @default.

• next